These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 12718828)

  • 1. Cytokines in immunodeficient patients with invasive fungal infections: an emerging therapy.
    Roilides E; Lamaignere CG; Farmaki E
    Int J Infect Dis; 2002 Sep; 6(3):154-63. PubMed ID: 12718828
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Granulocyte colony-stimulating factor and other cytokines in antifungal therapy.
    Roilides E; Farmaki E
    Clin Microbiol Infect; 2001; 7 Suppl 2():62-7. PubMed ID: 11525220
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of immunocompromised patients with evidence of an invasive mycosis.
    Walsh TJ
    Hematol Oncol Clin North Am; 1993 Oct; 7(5):1003-26. PubMed ID: 8226563
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytokines in the treatment of fungal infections.
    Kullberg BJ; van 't Wout JW
    Biotherapy; 1994; 7(3-4):195-210. PubMed ID: 7865351
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunomodulation with interferon-gamma and colony-stimulating factors for refractory fungal infections in patients with leukemia.
    Dignani MC; Rex JH; Chan KW; Dow G; deMagalhaes-Silverman M; Maddox A; Walsh T; Anaissie E
    Cancer; 2005 Jul; 104(1):199-204. PubMed ID: 15929126
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotherapy in patients with systemic mycoses: a promising adjunct.
    Farmaki E; Roilides E
    BioDrugs; 2001; 15(4):207-14. PubMed ID: 11437686
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antifungal immunity and adjuvant cytokine immune enhancement in cancer patients with invasive fungal infections.
    Safdar A
    Clin Microbiol Infect; 2007 Jan; 13(1):1-4. PubMed ID: 17184281
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent progress and current problems in management of invasive fungal infections in patients with neoplastic diseases.
    Walsh TJ; Lee JW; Roilides E; Pizzo PA
    Curr Opin Oncol; 1992 Aug; 4(4):647-55. PubMed ID: 1511021
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of fungal and other opportunistic infections in immunocompromised patients.
    Wade JC
    Leukemia; 1997 May; 11 Suppl 4():S38-9. PubMed ID: 9179282
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of immunoreconstitution in the management of refractory opportunistic fungal infections.
    Roilides E; Dignani MC; Anaissie EJ; Rex JH
    Med Mycol; 1998; 36 Suppl 1():12-25. PubMed ID: 9988488
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The potential role of cytokine therapy for fungal infections in patients with cancer: is recovery from neutropenia all that is needed?
    Rodriguez-Adrian LJ; Grazziutti ML; Rex JH; Anaissie EJ
    Clin Infect Dis; 1998 Jun; 26(6):1270-8. PubMed ID: 9636845
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High cure rate of invasive fungal infections in immunocompromised children using ambisome.
    Ringdén O; Tollemar J; Dahllöf G; Tydén G
    Transplant Proc; 1994 Feb; 26(1):175-7. PubMed ID: 8108927
    [No Abstract]   [Full Text] [Related]  

  • 13. Sphingolipids as Regulators of the Phagocytic Response to Fungal Infections.
    Bryan AM; Del Poeta M; Luberto C
    Mediators Inflamm; 2015; 2015():640540. PubMed ID: 26688618
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The rationale of combination antifungal therapy in severely immunocompromised patients: empiricism versus evidence-based medicine.
    Chamilos G; Kontoyiannis DP
    Curr Opin Infect Dis; 2006 Aug; 19(4):380-5. PubMed ID: 16804387
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytokines as antimicrobial therapy for the T cell-deficient patient: prospects for treatment of nonviral opportunistic infections.
    Murray HW
    Clin Infect Dis; 1993 Nov; 17 Suppl 2():S407-13. PubMed ID: 8274606
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined treatment: antifungal drugs with antibodies, cytokines or drugs.
    Stevens DA; Kullberg BJ; Brummer E; Casadevall A; Netea MG; Sugar AM
    Med Mycol; 2000; 38 Suppl 1():305-15. PubMed ID: 11204158
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fungal infections in the immunocompromised host.
    Wanke B; Lazéra Mdos S; Nucci M
    Mem Inst Oswaldo Cruz; 2000; 95 Suppl 1():153-8. PubMed ID: 11142705
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The immune response to fungal infections.
    Shoham S; Levitz SM
    Br J Haematol; 2005 Jun; 129(5):569-82. PubMed ID: 15916679
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recombinant interferon gamma1b immune enhancement in 20 patients with hematologic malignancies and systemic opportunistic infections treated with donor granulocyte transfusions.
    Safdar A; Rodriguez GH; Lichtiger B; Dickey BF; Kontoyiannis DP; Freireich EJ; Shpall EJ; Raad II; Kantarjian HM; Champlin RE
    Cancer; 2006 Jun; 106(12):2664-71. PubMed ID: 16691620
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design of efficacy trials of cytokines in combination with antifungal drugs.
    Kullberg BJ; Oude Lashof AM; Netea MG
    Clin Infect Dis; 2004 Oct; 39 Suppl 4():S218-23. PubMed ID: 15546121
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.